Issue Information
Issue highlights
Composite endpoints and the distortion of risk–benefit analysis
Poor reporting and documentation in drug‐associated Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis – Lessons for medication safety
The value of patient reporting to the pharmacovigilance system
Understanding and applying pharmacometric modelling and simulation in clinical practice and research
Microtubule destabilising agents
Managing drug–drug interactions with new direct‐acting antiviral agents in chronic hepatitis C
A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients
Population pharmacokinetics and analgesic potency of oxycodone
Pharmacokinetics and pharmacodynamics of PF‐05190457
Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects
Translating QT interval prolongation from conscious dogs to humans
Altered pharmacodynamics and pharmacokinetics of cisatracurium in patients with severe mitral valve regurgitation during anaesthetic induction period
Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator
An S‐warfarin and AZD1981 interaction
An assessment of the variation in the concentration of acetylcysteine in infusions for the treatment of paracetamol overdose
Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital
The impact of serious adverse drug reactions
Chemical gastritis and colitis related to hydrogen peroxide mouthwash
Contraindicated use of 5‐alpha‐reductase inhibitors in women
Endpoints in strategies to reduce polypharmacy
Reply to ‘Endpoints in strategies to reduce polypharmacy’
Discrepancies in paper by Chiam et al.